Immunotherapy company Atara Biotherapeutics Inc (Nasdaq:ATRA) announced on Friday that it awarded an aggregate of 140,861 restricted stock units of its common stock and stock options to purchase an aggregate of 124,966 shares of its common stock under Nasdaq Listing Rule 5635(c)(4).

With a grant date of 1 June 2021, the company announced the restricted stock units of its common stock to 28 newly hired employees and stock options to purchase its common stock to seven such newly hired employees

Subject to the employee's employment in the company of the vesting dates, the restricted stock units vest over four years, with 25% vesting on the first quarterly vesting date after the first anniversary of the grant date and the remainder vesting in 12 approximately equal quarterly installments over the following three years.

The company added that the stock options have a ten-year term and an exercise price of USD13.97 per share, equal to the per share closing price of its common stock on 1 June 2021. The stock options vest over four years, with 25% vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years.